Literature DB >> 6785800

A neuropharmacological analysis of the discriminative stimulus properties of fenfluramine.

F J White, J B Appel.   

Abstract

Rats were trained to discriminate fenfluramine (1.0 mg/kg) from saline in a two-lever drug discrimination task. The dose-response curve for this discrimination was orderly with an ED50 of about one-half of the training dose (0.52 mg/kg). In substitution tests, indirect (p-chloroamphetamine) and direct (quipazine, MK-212, lisuride) serotonin (5-HT) agonists substituted for fenfluramine. Since none of these compounds have been reported to be hallucinogenic and the potent hallucinogen LSD did not substitute completely, it was suggested that the discriminative stimulus properties of fenfluramine are not related to its ability to produce hallucinations in humans. The fenfluramine cue, like the quipazine cue, was antagonized by the 5-HT antagonists cyproheptadine and methiothepin. Unlike quipazine, fenfluramine was also partially antagonized by the 5-HT uptake inhibitor, fluoxetine, and the 5-HT synthesis inhibitor, p-chlorophenylalanine. Thus, the fenfluramine cue differs from that of quipazine in that it is mediated via indirect actions on 5-HT receptors. Since the indirect dopamine (DA) agonist d-amphetamine failed to substitute and the DA antagonist haloperidol failed to block the fenfluramine cue, a mediating role for DA was not indicated. Another indirect DA agonist, cocaine, substituted partially for fenfluramine, a result which paralleled that seen with fluoxetine. Both of these partial substitutions were reduced by cyproheptadine; therefore, it was concluded that these effects may be due to the common ability of cocaine, fluoxetine, and fenfluramine to inhibit 5-HT uptake.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785800     DOI: 10.1007/BF00429199

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis.

Authors:  L Pieri; H H Keller; W Burkard; M Da Prada
Journal:  Nature       Date:  1978-03-16       Impact factor: 49.962

2.  Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD.

Authors:  M Pieri; R Schaffner; L Pieri; M Da Prada; W Haefely
Journal:  Life Sci       Date:  1978-05-08       Impact factor: 5.037

3.  Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140).

Authors:  R W Fuller; K W Perry; B B Molloy
Journal:  Life Sci       Date:  1974-09-15       Impact factor: 5.037

Review 4.  The mechanism of action of fenfluramine.

Authors:  S Garattini; W Buczko; A Jori; R Samanin
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

5.  The anorectic activity of fenfluramine.

Authors:  J T Silverstone; J Fincham; D B Campbell
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

6.  The role of dopamine in the discriminative stimulus properties of cocaine.

Authors:  M L McKenna; B T Ho
Journal:  Neuropharmacology       Date:  1980-03       Impact factor: 5.250

7.  Delta 9-Tetrahydrocannabinol, ethanol, and amphetamine as discriminative stimuli-generalization tests with other drugs.

Authors:  O F Bueno; E A Carlini; E Finkelfarb; J S Suzuki
Journal:  Psychopharmacologia       Date:  1976-04-15

8.  High-affinity binding of (3H) 5-hydroxytryptamine to brain synaptosomal membranes: comparison with (3H) lysergic acid diethylamide binding.

Authors:  G M Fillion; J C Rousselle; M P Fillion; D M Beaudoin; M R Goiny; J M Deniau; J J Jacob
Journal:  Mol Pharmacol       Date:  1978-01       Impact factor: 4.436

9.  Effects of opiates on the discriminative stimulus properties of dopamine agonists.

Authors:  L L Hernandez; A M Holohean; J B Appel
Journal:  Pharmacol Biochem Behav       Date:  1978-10       Impact factor: 3.533

10.  Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus.

Authors:  J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  8 in total

1.  Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys.

Authors:  Jessica McClung; William Fantegrossi; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

2.  Discriminative stimulus properties of the serotonin agonist MK 212.

Authors:  K A Cunningham; P M Callahan; J B Appel
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Serotonin transporter protein in autopsied brain of chronic users of cocaine.

Authors:  Junchao Tong; Jeffrey H Meyer; Isabelle Boileau; Lee-Cyn Ang; Paul J Fletcher; Yoshiaki Furukawa; Stephen J Kish
Journal:  Psychopharmacology (Berl)       Date:  2020-06-03       Impact factor: 4.530

4.  The rise (and fall?) of drug discrimination research.

Authors:  Lance R McMahon
Journal:  Drug Alcohol Depend       Date:  2015-06-01       Impact factor: 4.492

5.  Discriminative stimulus properties of fenfluramine: evidence for serotonergic involvement.

Authors:  J F McElroy; R S Feldman
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  The interoceptive discriminative stimuli induced by the novel putative anxiolytic TVX Q 7821: behavioral evidence for the specific involvement of serotonin 5-HT1A receptors.

Authors:  D G Spencer; J Traber
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Additional evidence that L-5-hydroxytryptophan discrimination models a unique serotonin receptor.

Authors:  R Friedman; R J Barrett; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  Drug discrimination studies with MDMA and amphetamine.

Authors:  R Oberlender; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.